Business
Gemini Therapeutics to Participate in the Jefferies Virtual Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments
About this update from Disc Medicine, Inc.
[{"type":"text","content":" CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nGemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced that Jason Meyenburg, Chief Executive Officer of Gemini Therapeutics, is scheduled to participate virtually in the Jefferies Virtual Healthcare Conference on Wednesday, June 2 at 3:30 PM ET.\n\nA live webcast of the event will be available on the \"Events & Presentations\" page on the Company's website. A replay of the webcast will be archived on the Company's website for 30 days following the presentation.\n\nAbout Gemini Therapeutics\n\nGemini Therapeutics is a clinical stage precision medicine company developing novel therapeutic compounds to treat genetically defined age-related macular degeneration (AMD). Gemini’s lead candidate, GEM103, is a recombinant form of human complement factor H protein (CFH) and is designed to address both complement hyperactivity and restore retinal health in patients with AMD. GEM103 is currently in a Phase 2a trial in dry AMD patients with a CFH risk variant and a Phase 1/2a study in patients with neovascular age-related macular degeneration with or at risk for macular atrophy. The company has generated a rich pipeline including recombinant proteins, gene therapies, and monoclonal antibodies and is advancing a potentiating antibody for CFH, GEM307, into clinical development for treatment of systemic diseases.\n\nFor more information, visit www.geminitherapeutics.com.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210526005186/en/\n\nGemini Investor Contact:\nArgot Partners\nSherri Spear\n212-600-1902\[email protected]\n\nGemini Media Contact:\nArgot Partners\nJoshua Mansbach\n212-600-1902\[email protected]\n\nSource: Gemini Therapeutics, Inc.","length":3407,"tagName":"div"}]